THU0126 Impact of residential area on the profile of rheumatoid arthritis patients initiating their first biologic dmard: results from the ontario best practices research initiative (OBRI)
Authors: R. Joshi, M. Movahedi, E. Rampakakis, C. Thorne, A. Cesta, J.S. Sampalis, C. Bombardier
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Access to care and management of Rheumatoid Arthritis (RA) patients may differ based on residential area which, in turn, can affect the real-world effectiveness of anti-rheumatic medications. <h3>Objectives</h3> We aimed to describe differences in the profile of patients initiating their first biologic disease modifying antirheumatic drug (bDMARD) based on their residence in urban vs. rural areas. <h3>Methods</h3> RA patients enrolled in the OBRI initiating their first bDMARD within 30 days prior to or anytime following enrolment were included in the analysis. Patients excluded if they had less than 2 years of follow-up and less than 2 visits during this period of time. Patients characteristics included sociodemographics (age, gender, race, education level, marital status, smoking status, annual household income, health insurance coverage), disease duration, disease severity parameters (Disease Activity Score (DAS), Clinical Disease Activity Index (CDAI), Swollen and Tender Joints (SJC28, TJC28), Physician Global Assessment (PhGA), Patient Global Assessment (PGA), Health Assessment Questionnaire – Disability Index (HAQ-DI), presence of erosion), bDMARD type, and concomitant anti-rheumatic medications including conventional synthetic disease modifying antirheumatic drug (csDMARDs), non-steroidal anti-inflammatory drugs (NSAIDs), and oral steroids. <h3>Results</h3> A total of 629 RA patients were included of whom 522 (83%) resided in urban areas and 107 (17%) in rural areas. Other than marital status (urban vs. rural: 64.6% vs. 82.2% married; p&lt;0.001) and race (urban vs. rural: 78.0% vs. 95.3% Caucasian; p=0.001) no significant differences in sociodemographics were observed between groups. However, patients from urban areas were less likely to have an erosion (46.6% vs. 50.5%; p=0.23), had lower TJC28 (7.2 vs. 7.9; p=0.43), and lower SJC28 (6.6 vs. 7.1; p=0.42) at bDMARD initiation. Type of bDMARD (anti-TNF vs. other mechanism of action) was comparable between groups (87.9% on anti-TNF) as was concomitant treatment with csDMARDs (84.9% on csDMARDs), and NSAIDs (19.6% on NSAIDs). Concomitant use of oral steroids was significantly lower in patients from urban areas (21.5% vs 29.9%; p=0.04). <h3>Conclusions</h3> Important differences may exist in the profiles of RA patients initiating their first bDMARD, and residing in rural versus urban areas. The implications on treatment outcomes should be assessed. <h3>Disclosure of Interest</h3> R. Joshi Grant/research support from: OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and unrestricted grants from: Abbvie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB, M. Movahedi Employee of: OBRI, E. Rampakakis Employee of: JSS Medical Research, C. Thorne Grant/research support from: OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and unrestricted grants from: Abbvie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB, A. Cesta Employee of: OBRI, J. Sampalis: None declared, C. Bombardier Grant/research support from: OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and unrestricted grants from: Abbvie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB, Consultant for: Canada Research Chair in Knowledge Transfer for Musculoskeletal Care and a Pfizer Research Chair in Rheumatology